Mirikizumab for colitis, ulcerative

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 9 May 2018: Trial registered, NCT03519945
  2. 18 Jul 2018: Trial started, NCT03519945

The trials

NCT03519945: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

State
Under way
Phase
Phase 3
People
1,058 taking part
Started
18 Jul 2018
Primary completion
4 Mar 2026
Arms
Mirikizumab
Results
None posted
  1. 9 May 2018: Trial registered
  2. 18 Jul 2018: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.